Details of Disease

Disease Name

Esophageal adenocarcinoma

esophageal adenocarcinoma; oesophagus adenocarcinoma; adenocarcinoma of the oesophagus; adenocarcinoma of esophagus; adenocarcinoma of the esophagus; esophagus adenocarcinoma; oesophageal adenocarcinoma; adenocarcinoma - oesophagus; adenocarcinoma of oesophagus; adenocarcinoma - esophagus

Definition

A malignant tumor with glandular differentiation arising predominantly from Barrett mucosa in the lower third of the esophagus. Rare examples of esophageal adenocarcinoma deriving from ectopic gastric mucosa in the upper esophagus have also been reported. Grossly, esophageal adenocarcinomas are similar to esophageal squamous cell carcinomas. Microscopically, adenocarcinomas arising in the setting of Barrett esophagus are typically papillary and/or tubular. The prognosis is poor.

Disease Hierarchy

DIS3IHTY: Adenocarcinoma

DISS6G4D: Carcinoma of esophagus

DISODWFP: Esophageal adenocarcinoma

Disease Identifiers

MONDO ID

MONDO_0005028

MESH ID

C562730

UMLS CUI

C0279628

MedGen ID

124636

Orphanet ID

99976

SNOMED CT ID

276803003

General Information of Disease (ID: DISODWFP)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 38 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AXL	TTZPY6J	Limited	Biomarker	[1]
OLFM4	TTK1CX7	Limited	Altered Expression	[2]
TLR4	TTISGCA	Limited	Biomarker	[3]
CDK9	TT1LVF2	moderate	Biomarker	[4]
CDKN2A	TTFTWQ8	moderate	Biomarker	[5]
FOXP1	TT0MUCI	moderate	Biomarker	[6]
ANXA10	TT0NL6U	Strong	Biomarker	[7]
APOB	TTN1IE2	Strong	Genetic Variation	[8]
ASPA	TT6TLZP	Strong	Altered Expression	[9]
ATP4A	TTF1QVM	Strong	Genetic Variation	[10]
BECN1	TT5M7LN	Strong	Biomarker	[11]
CCN1	TTPK79J	Strong	Altered Expression	[12]
CDC25B	TTR0SWN	Strong	Altered Expression	[13]
CDK8	TTBJR4L	Strong	Altered Expression	[14]
CFTR	TTRLZHP	Strong	Altered Expression	[15]
CRTC1	TT4GO0F	Strong	Genetic Variation	[16]
CTSE	TTLXC4Q	Strong	Altered Expression	[17]
EPCAM	TTZ8WH4	Strong	Biomarker	[18]
FGF1	TTMY81X	Strong	Altered Expression	[19]
FKBP5	TT0J5KQ	Strong	Biomarker	[20]
MAGEA4	TT9EQUY	Strong	Biomarker	[21]
MAGEA6	TTJIWMO	Strong	Altered Expression	[22]
MAPKAPK2	TTMUG9D	Strong	Altered Expression	[23]
MMP12	TTXZ0KQ	Strong	Genetic Variation	[24]
MUC5AC	TTEL90S	Strong	Biomarker	[25]
NELL1	TT7H4BF	Strong	Biomarker	[26]
NQO2	TTJLP0R	Strong	Genetic Variation	[27]
NR1H4	TTS4UGC	Strong	Altered Expression	[28]
PRKCZ	TTBSN0L	Strong	Biomarker	[29]
PTGER2	TT1ZAVI	Strong	Altered Expression	[30]
PTGES	TTYLQ8V	Strong	Biomarker	[31]
PTGS1	TT8NGED	Strong	Biomarker	[32]
REG4	TTVZEHU	Strong	Biomarker	[33]
RPS6KB1	TTG0U4H	Strong	Biomarker	[34]
S1PR2	TTVSMOH	Strong	Biomarker	[35]
SERPINB3	TT6QLPX	Strong	Biomarker	[36]
SLC6A8	TTYUHB5	Strong	Biomarker	[37]
VSIR	TT51SK8	Strong	Altered Expression	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 38 DTT(s)

This Disease Is Related to 4 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC5	DTYVM24	Strong	Biomarker	[16]
ATP12A	DT5NLZA	Strong	Genetic Variation	[10]
SLC35A2	DT0567K	Strong	Genetic Variation	[39]
SLC52A3	DTBVQIO	Strong	Biomarker	[40]
------------------------------------------------------------------------------------

This Disease Is Related to 5 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
AKR1C2	DEOY5ZM	Limited	Altered Expression	[41]
ALDH1A2	DEKN1H4	Strong	Genetic Variation	[16]
HIF1AN	DEY1CBW	Strong	Genetic Variation	[42]
MSRA	DEU2ZBY	Strong	Genetic Variation	[16]
UGT2B17	DEAZDL8	Strong	Altered Expression	[43]
------------------------------------------------------------------------------------

This Disease Is Related to 84 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AMPD1	OTU17BCI	Limited	Altered Expression	[44]
ARID1A	OTRWDV3P	Limited	Biomarker	[45]
BARX1	OT2VP73H	Limited	Genetic Variation	[46]
ETV4	OT8C98UZ	Limited	Altered Expression	[47]
MAX	OTKZ0YKM	Limited	Altered Expression	[44]
MEGF8	OT5G38CH	Limited	Genetic Variation	[48]
COX2	OTTMVBJJ	moderate	Altered Expression	[49]
DECR1	OTCDIR6X	moderate	Biomarker	[50]
DOCK2	OTZTS3PA	moderate	Biomarker	[51]
ELMO1	OTY2ORXK	moderate	Biomarker	[51]
FGF13	OTHNNVSG	moderate	Biomarker	[52]
NUDT6	OTCS3NYZ	moderate	Biomarker	[53]
SPART	OTIVOS2I	moderate	Biomarker	[51]
A1CF	OTJBKFA1	Strong	Altered Expression	[9]
AFAP1	OTR473H8	Strong	Altered Expression	[54]
ARF6	OTVV7KJO	Strong	Biomarker	[55]
ASZ1	OTLM93UO	Strong	Genetic Variation	[16]
BCAS3	OTDVAX6B	Strong	Altered Expression	[9]
BFAR	OTTBG0V7	Strong	Biomarker	[56]
CD151	OTF3UZS7	Strong	Biomarker	[57]
CDH17	OT9EV2XK	Strong	Biomarker	[58]
CDX2	OTCG4TSY	Strong	Biomarker	[59]
CEP72	OTVYNPNL	Strong	Genetic Variation	[16]
CLDN2	OTRF3D6Y	Strong	Altered Expression	[60]
COLQ	OT4BHUGQ	Strong	Genetic Variation	[61]
COX1	OTG3O9BN	Strong	Biomarker	[62]
CRNKL1	OTWBQNGU	Strong	Biomarker	[63]
CYGB	OTX153DQ	Strong	Altered Expression	[64]
CYLD	OT37FKH0	Strong	Genetic Variation	[61]
EIF4A2	OT08H03R	Strong	Altered Expression	[65]
EIF4G1	OT2CF1E6	Strong	Altered Expression	[65]
EMX2	OT0V8OYK	Strong	Biomarker	[66]
EPC1	OT3Q25ND	Strong	Biomarker	[67]
EPC2	OTTG0W9R	Strong	Genetic Variation	[67]
ERCC2	OT1C8HQ4	Strong	Genetic Variation	[68]
ETV1	OT6PMJIK	Strong	Altered Expression	[23]
FOXF1	OT2CJZ5K	Strong	Genetic Variation	[69]
FRZB	OTTO3DPY	Strong	Posttranslational Modification	[70]
GDF7	OTNZY74B	Strong	Genetic Variation	[71]
GOLM1	OTOZSV6O	Strong	Biomarker	[72]
GPX7	OTINT9Z4	Strong	Altered Expression	[73]
HGD	OTTKLQOO	Strong	Biomarker	[74]
HTR3C	OT65ZLIJ	Strong	Genetic Variation	[16]
ITGA3	OTBCH21D	Strong	Altered Expression	[13]
KHDRBS2	OTEKL45T	Strong	Genetic Variation	[16]
KLF12	OTVH4KD4	Strong	Biomarker	[75]
LIN54	OTPC9LQI	Strong	Biomarker	[76]
MAGEB6	OTOTV1FU	Strong	Biomarker	[77]
MAP2K6	OTK13JKC	Strong	Biomarker	[78]
MPG	OTAHW80B	Strong	Altered Expression	[79]
MSX1	OT5U41ZP	Strong	Genetic Variation	[80]
MUC5B	OTPW6K5C	Strong	Biomarker	[25]
MUCL1	OT9QUFL3	Strong	Biomarker	[81]
MUS81	OTVZ4E60	Strong	Biomarker	[82]
MYO9B	OTQ94R5K	Strong	Biomarker	[83]
NOC2L	OTNT7R33	Strong	Biomarker	[84]
NOX5	OTHTH59G	Strong	Biomarker	[85]
OR12D3	OTQ9XNBB	Strong	Genetic Variation	[16]
OR5V1	OTSYXOD6	Strong	Genetic Variation	[16]
PIGA	OT51UWUR	Strong	Genetic Variation	[86]
PITX1	OTA0UN4C	Strong	Altered Expression	[87]
PKP1	OT9HSQ8F	Strong	Biomarker	[88]
PLCE1	OTJISZOX	Strong	Biomarker	[40]
PTRH2	OTBU39Q1	Strong	Altered Expression	[89]
RAB40B	OTCA9ZF5	Strong	Altered Expression	[90]
RBM3	OTAJ7R31	Strong	Altered Expression	[91]
RBM38	OTPO8EXU	Strong	Biomarker	[92]
RBM43	OTANIFBG	Strong	Genetic Variation	[93]
RFC3	OT1MS7AO	Strong	Biomarker	[94]
RND3	OTXMXPIH	Strong	Genetic Variation	[93]
ROPN1L	OTRWZJ68	Strong	Altered Expression	[9]
RRAD	OTW2O4GD	Strong	Posttranslational Modification	[95]
SERPINB4	OT88LHZ8	Strong	Biomarker	[36]
SKI	OT4KJ8F6	Strong	Biomarker	[29]
SMTN	OT4R2TYK	Strong	Biomarker	[96]
SPAG11A	OTNQ9UB0	Strong	Altered Expression	[30]
TCOF1	OT4BOYTM	Strong	Genetic Variation	[97]
TMOD1	OTTRYF9Y	Strong	Genetic Variation	[16]
TPPP	OTCFMSUF	Strong	Genetic Variation	[16]
TRIM31	OT7VW6RP	Strong	Altered Expression	[98]
TSPAN18	OTHSGPVB	Strong	Biomarker	[81]
APOBEC1	OTY8QX2R	Definitive	Altered Expression	[99]
GATA5	OTO81B63	Definitive	Posttranslational Modification	[100]
KRT13	OTTYSKGX	Definitive	Biomarker	[101]
------------------------------------------------------------------------------------


⏷ Show the Full List of 84 DOT(s)

References

1	AXL Mediates Esophageal Adenocarcinoma Cell Invasion through Regulation of Extracellular Acidification and Lysosome Trafficking.Neoplasia. 2018 Oct;20(10):1008-1022. doi: 10.1016/j.neo.2018.08.005. Epub 2018 Sep 3.
2	Olfactomedin 4 (OLFM4) expression is associated with nodal metastases in esophageal adenocarcinoma.PLoS One. 2019 Jul 8;14(7):e0219494. doi: 10.1371/journal.pone.0219494. eCollection 2019.
3	Toll-Like Receptor-4 Is a Mediator of Proliferation in Esophageal Adenocarcinoma.Ann Thorac Surg. 2019 Jan;107(1):233-241. doi: 10.1016/j.athoracsur.2018.08.014. Epub 2018 Oct 4.
4	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma.Oncotarget. 2019 Jul 23;10(45):4703-4718. doi: 10.18632/oncotarget.27095. eCollection 2019 Jul 23.
5	A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett's oesophagus to oesophageal adenocarcinoma.BMJ Open. 2018 Jun 30;8(6):e020427. doi: 10.1136/bmjopen-2017-020427.
6	Supportive evidence for FOXP1, BARX1, and FOXF1 as genetic risk loci for the development of esophageal adenocarcinoma.Cancer Med. 2015 Nov;4(11):1700-4. doi: 10.1002/cam4.500. Epub 2015 Aug 15.
7	A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma.Cell Oncol. 2008;30(1):63-75. doi: 10.1155/2008/328529.
8	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases.Nat Commun. 2019 Sep 16;10(1):4219. doi: 10.1038/s41467-019-11968-2.
9	Multiple forms of genetic instability within a 2-Mb chromosomal segment of 3q26.3-q27 are associated with development of esophageal adenocarcinoma.Genes Chromosomes Cancer. 2006 Apr;45(4):319-31. doi: 10.1002/gcc.20293.
10	Omeprazole prevents CDX2 and SOX9 expression by inhibiting hedgehog signaling in Barrett's esophagus cells.Clin Sci (Lond). 2019 Feb 12;133(3):483-495. doi: 10.1042/CS20180828. Print 2019 Feb 14.
11	Expression, modulation, and clinical correlates of the autophagy protein Beclin-1 in esophageal adenocarcinoma.Mol Carcinog. 2016 Nov;55(11):1876-1885. doi: 10.1002/mc.22432. Epub 2015 Nov 19.
12	CCN1 induces apoptosis in esophageal adenocarcinoma through p53-dependent downregulation of survivin.J Cell Biochem. 2019 Feb;120(2):2070-2077. doi: 10.1002/jcb.27515. Epub 2018 Sep 11.
13	Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues.Anticancer Res. 2003 Jan-Feb;23(1A):161-5.
14	Identifying Cancers Impacted by CDK8/19.Cells. 2019 Aug 3;8(8):821. doi: 10.3390/cells8080821.
15	CFTR inhibits the invasion and growth of esophageal cancer cells by inhibiting the expression of NF-B.Cell Biol Int. 2018 Dec;42(12):1680-1687. doi: 10.1002/cbin.11069.
16	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12.
17	High Expression of Cathepsin E in Tissues but Not Blood of Patients with Barrett's Esophagus and Adenocarcinoma.Ann Surg Oncol. 2015 Jul;22(7):2431-8. doi: 10.1245/s10434-014-4155-y. Epub 2014 Oct 28.
18	Identification of Tumor Specific Peptide as EpCAM Ligand and Its Potential Diagnostic and Therapeutic Clinical Application.Mol Pharm. 2019 May 6;16(5):2199-2213. doi: 10.1021/acs.molpharmaceut.9b00185. Epub 2019 Apr 18.
19	Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma.Histopathology. 1999 Jul;35(1):31-7. doi: 10.1046/j.1365-2559.1999.00657.x.
20	Androgen Signaling in Esophageal Adenocarcinoma Cell Lines In Vitro.Dig Dis Sci. 2017 Dec;62(12):3402-3414. doi: 10.1007/s10620-017-4794-5. Epub 2017 Oct 20.
21	Intensity-modulated radiotherapy at high-volume centers improves survival in patients with esophageal adenocarcinoma receiving trimodality therapy.Dis Esophagus. 2019 Aug 1;32(8):doy124. doi: 10.1093/dote/doy124.
22	Investigation into the expression levels of MAGEA6 in esophageal squamous cell carcinoma and esophageal adenocarcinoma tissues.Exp Ther Med. 2019 Sep;18(3):1816-1822. doi: 10.3892/etm.2019.7735. Epub 2019 Jul 5.
23	MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas.J Cancer. 2018 Jan 1;9(3):460-468. doi: 10.7150/jca.22310. eCollection 2018.
24	Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.Carcinogenesis. 2009 May;30(5):793-8. doi: 10.1093/carcin/bgp065. Epub 2009 Mar 25.
25	Elucidation of the AGR2 Interactome in Esophageal Adenocarcinoma Cells Identifies a Redox-Sensitive Chaperone Hub for the Quality Control of MUC-5AC.Antioxid Redox Signal. 2019 Nov 20;31(15):1117-1132. doi: 10.1089/ars.2018.7647. Epub 2019 Sep 25.
26	Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene. 2007 Sep 20;26(43):6332-40. doi: 10.1038/sj.onc.1210461. Epub 2007 Apr 23.
27	Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis.Mol Biol Rep. 2012 Sep;39(9):9095-104. doi: 10.1007/s11033-012-1781-y. Epub 2012 Jun 27.
28	TGR5 expression in benign, preneoplastic and neoplastic lesions of Barrett's esophagus: Case series and findings.World J Gastroenterol. 2017 Feb 28;23(8):1338-1344. doi: 10.3748/wjg.v23.i8.1338.
29	Copy number alterations detected by whole-exome and whole-genome sequencing of esophageal adenocarcinoma.Hum Genomics. 2015 Sep 15;9(1):22. doi: 10.1186/s40246-015-0044-0.
30	Prostaglandin EP2 receptor expression is increased in Barrett's oesophagus and oesophageal adenocarcinoma.Aliment Pharmacol Ther. 2010 Feb 1;31(3):440-51. doi: 10.1111/j.1365-2036.2009.04172.x. Epub 2009 Oct 16.
31	NADPH oxidase NOX5-S and nuclear factor B1 mediate acid-induced microsomal prostaglandin E synthase-1 expression in Barrett's esophageal adenocarcinoma cells.Mol Pharmacol. 2013 May;83(5):978-90. doi: 10.1124/mol.112.083287. Epub 2013 Feb 25.
32	Characterization of the prostaglandin E2 pathway in a rat model of esophageal adenocarcinoma.Curr Cancer Drug Targets. 2012 Feb;12(2):132-43. doi: 10.2174/156800912799095199.
33	Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths.Transl Oncol. 2018 Feb;11(1):116-124. doi: 10.1016/j.tranon.2017.10.003. Epub 2017 Dec 18.
34	RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas.Cancer Res. 2016 Oct 1;76(19):5628-5633. doi: 10.1158/0008-5472.CAN-16-0979. Epub 2016 Aug 8.
35	Therapeutic Role of Sphingosine-1-Phosphate Receptor 2 in the Progression of Esophageal Adenocarcinoma.Am J Pathol. 2018 Sep;188(9):1949-1952. doi: 10.1016/j.ajpath.2018.07.001. Epub 2018 Jul 17.
36	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity.Cancer Sci. 2019 May;110(5):1552-1563. doi: 10.1111/cas.13986. Epub 2019 Apr 15.
37	Visceral Adipose Tissue Modulates Radiosensitivity in Oesophageal Adenocarcinoma.Int J Med Sci. 2019 Apr 5;16(4):519-528. doi: 10.7150/ijms.29296. eCollection 2019.
38	The expression of the immune checkpoint regulator VISTA correlates with improved overall survival in pT1/2 tumor stages in esophageal adenocarcinoma.Oncoimmunology. 2019 Feb 27;8(5):e1581546. doi: 10.1080/2162402X.2019.1581546. eCollection 2019.
39	High enzyme activity UGT1A1 or low activity UGT1A8 and UGT2B4 genotypes increase esophageal cancer risk.Int J Oncol. 2012 Jun;40(6):1789-96. doi: 10.3892/ijo.2012.1385. Epub 2012 Feb 22.
40	GWAS-uncovered SNPs in PLCE1 and RFT2 genes are not implicated in Dutch esophageal adenocarcinoma and squamous cell carcinoma etiology.Eur J Cancer Prev. 2013 Sep;22(5):417-9. doi: 10.1097/CEJ.0b013e32835c7f53.
41	Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma.J Proteome Res. 2008 May;7(5):1953-62. doi: 10.1021/pr7007835. Epub 2008 Apr 9.
42	Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study.Cancer. 2012 Feb 1;118(3):804-11. doi: 10.1002/cncr.26325. Epub 2011 Jul 12.
43	UGT2B17 and miR-224 contribute to hormone dependency trends in adenocarcinoma and squamous cell carcinoma of esophagus.Biosci Rep. 2019 Jul 5;39(7):BSR20190472. doi: 10.1042/BSR20190472. Print 2019 Jul 31.
44	Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network.Br J Cancer. 2008 Jun 17;98(12):1985-92. doi: 10.1038/sj.bjc.6604398. Epub 2008 May 20.
45	Loss of ARID1A expression is associated with DNA mismatch repair protein deficiency and favorable prognosis in advanced stage surgically resected esophageal adenocarcinoma.Hum Pathol. 2019 Dec;94:1-10. doi: 10.1016/j.humpath.2019.09.004. Epub 2019 Oct 24.
46	An esophageal adenocarcinoma susceptibility locus at 9q22 also confers risk to esophageal squamous cell carcinoma by regulating the function of BARX1.Cancer Lett. 2018 May 1;421:103-111. doi: 10.1016/j.canlet.2018.02.019. Epub 2018 Feb 14.
47	The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma.Mol Cancer. 2010 Dec 9;9:313. doi: 10.1186/1476-4598-9-313.
48	Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity.Clin Cancer Res. 2010 Apr 1;16(7):2009-21. doi: 10.1158/1078-0432.CCR-09-2801. Epub 2010 Mar 23.
49	Cyclo-oxygenase-2 expression is associated with mean standardised uptake value on 18F-Fluorodeoxyglucose positron emission tomography in oesophageal adenocarcinoma.Br J Radiol. 2019 Jul;92(1099):20180668. doi: 10.1259/bjr.20180668. Epub 2019 May 8.
50	Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells.Am J Physiol Cell Physiol. 2011 Aug;301(2):C413-20. doi: 10.1152/ajpcell.00027.2011. Epub 2011 Apr 27.
51	Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.Nat Genet. 2013 May;45(5):478-86. doi: 10.1038/ng.2591. Epub 2013 Mar 24.
52	Regulation of FGF-2 by an endogenous antisense RNA: effects on cell adhesion and cell-cycle progression.Mol Carcinog. 2010 Dec;49(12):1031-44. doi: 10.1002/mc.20686.
53	Alternative splicing of the FGF antisense gene: differential subcellular localization in human tissues and esophageal adenocarcinoma.J Mol Med (Berl). 2007 Nov;85(11):1215-28. doi: 10.1007/s00109-007-0219-9. Epub 2007 Jun 14.
54	Long noncoding RNA actin filament-associated protein 1 antisense RNA 1 promotes malignant phenotype through binding with lysine-specific demethylase 1 and repressing HMG box-containing protein 1 in non-small-cell lung cancer.Cancer Sci. 2019 Jul;110(7):2211-2225. doi: 10.1111/cas.14039. Epub 2019 May 29.
55	APE1 Upregulates MMP-14 via Redox-Sensitive ARF6-Mediated Recycling to Promote Cell Invasion of Esophageal Adenocarcinoma.Cancer Res. 2019 Sep 1;79(17):4426-4438. doi: 10.1158/0008-5472.CAN-19-0237. Epub 2019 Jul 15.
56	Role of NADPH oxidase NOX5-S, NF-B, and DNMT1 in acid-induced p16 hypermethylation in Barrett's cells.Am J Physiol Cell Physiol. 2013 Nov 15;305(10):C1069-79. doi: 10.1152/ajpcell.00080.2013. Epub 2013 Sep 11.
57	CD151 Gene and Protein Expression Provides Independent Prognostic Information for Patients with Adenocarcinoma of the Esophagus and Gastroesophageal Junction Treated by Esophagectomy.Ann Surg Oncol. 2016 Dec;23(Suppl 5):746-754. doi: 10.1245/s10434-016-5504-9. Epub 2016 Aug 30.
58	Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesis.Dig Dis Sci. 2013 Mar;58(3):699-705. doi: 10.1007/s10620-012-2425-8. Epub 2012 Oct 4.
59	Barrett's esophagus: cancer and molecular biology.Ann N Y Acad Sci. 2013 Oct;1300:296-314. doi: 10.1111/nyas.12252.
60	High expression of Claudin-2 in esophageal carcinoma and precancerous lesions is significantly associated with the bile salt receptors VDR and TGR5.BMC Gastroenterol. 2017 Feb 17;17(1):33. doi: 10.1186/s12876-017-0590-0.
61	Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.Mol Cancer. 2018 Feb 19;17(1):54. doi: 10.1186/s12943-018-0790-4.
62	Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.EBioMedicine. 2019 Nov;49:145-156. doi: 10.1016/j.ebiom.2019.10.038. Epub 2019 Nov 7.
63	Protein coding gene CRNKL1 as a potential prognostic biomarker in esophageal adenocarcinoma.Artif Intell Med. 2017 Feb;76:1-6. doi: 10.1016/j.artmed.2017.01.002. Epub 2017 Jan 22.
64	Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.BMC Cancer. 2016 Jul 19;16:497. doi: 10.1186/s12885-016-2544-2.
65	Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype.Cancer Gene Ther. 2012 Sep;19(9):609-18. doi: 10.1038/cgt.2012.39. Epub 2012 Jul 6.
66	EMX2 is epigenetically silenced and suppresses epithelialmesenchymal transition in human esophageal adenocarcinoma.Oncol Rep. 2019 Nov;42(5):2169-2178. doi: 10.3892/or.2019.7284. Epub 2019 Aug 20.
67	In-depth characterization of the Wnt-signaling/-catenin pathway in an in vitro model of Barrett's sequence.BMC Gastroenterol. 2019 Mar 6;19(1):38. doi: 10.1186/s12876-019-0957-5.
68	A pooled analysis of the ERCC2 Asp312Asn polymorphism and esophageal cancer susceptibility.Tumour Biol. 2014 Apr;35(4):2959-65. doi: 10.1007/s13277-013-1380-0.
69	Prognostic impact of FOXF1 polymorphisms in gastric cancer patients.Pharmacogenomics J. 2018 Apr;18(2):262-269. doi: 10.1038/tpj.2017.9. Epub 2017 Apr 11.
70	Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.Int J Cancer. 2005 Sep 10;116(4):584-91. doi: 10.1002/ijc.21045.
71	The Barrett-associated variants at GDF7 and TBX5 also increase esophageal adenocarcinoma risk.Cancer Med. 2016 May;5(5):888-91. doi: 10.1002/cam4.641. Epub 2016 Jan 18.
72	Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion.Br J Cancer. 2015 Nov 3;113(9):1332-42. doi: 10.1038/bjc.2015.350. Epub 2015 Oct 13.
73	Glutathione peroxidase 7 protects against oxidative DNA damage in oesophageal cells.Gut. 2012 Sep;61(9):1250-60. doi: 10.1136/gutjnl-2011-301078. Epub 2011 Dec 9.
74	Inflammation and Barrett's carcinogenesis.Pathol Res Pract. 2012 May 15;208(5):269-80. doi: 10.1016/j.prp.2012.03.007. Epub 2012 Apr 27.
75	Krppel-Like Factor 12 Promotes Colorectal Cancer Growth through Early Growth Response Protein 1.PLoS One. 2016 Jul 21;11(7):e0159899. doi: 10.1371/journal.pone.0159899. eCollection 2016.
76	Deregulation of the FOXM1 target gene network and its coregulatory partners in oesophageal adenocarcinoma.Mol Cancer. 2015 Mar 26;14:69. doi: 10.1186/s12943-015-0339-8.
77	Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.J Gastrointest Surg. 2012 Jan;16(1):26-34; discussion 34. doi: 10.1007/s11605-011-1700-x. Epub 2011 Sep 29.
78	Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma.Cell Signal. 2018 Nov;51:222-232. doi: 10.1016/j.cellsig.2018.08.008. Epub 2018 Aug 11.
79	Diagnostic correlation between the expression of the DNA repair enzyme N-methylpurine DNA glycosylase and esophageal adenocarcinoma onset: a retrospective pilot study.Dis Esophagus. 2013 Aug;26(6):644-50. doi: 10.1111/dote.12003. Epub 2012 Nov 8.
80	Germline variant in MSX1 identified in a Dutch family with clustering of Barrett's esophagus and esophageal adenocarcinoma.Fam Cancer. 2018 Jul;17(3):435-440. doi: 10.1007/s10689-017-0054-2.
81	Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR.Clin Cancer Res. 2005 Mar 15;11(6):2205-14. doi: 10.1158/1078-0432.CCR-04-1091.
82	Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.Sci Rep. 2018 May 8;8(1):7265. doi: 10.1038/s41598-018-24232-2.
83	Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.Scand J Gastroenterol. 2012 Dec;47(12):1422-8. doi: 10.3109/00365521.2012.722673. Epub 2012 Sep 7.
84	NIR absorbing reduced graphene oxide for photothermal radiotherapy for treatment of esophageal cancer.J Photochem Photobiol B. 2019 May;194:188-193. doi: 10.1016/j.jphotobiol.2019.03.014. Epub 2019 Mar 22.
85	Rho Kinase ROCK2 Mediates Acid-Induced NADPH Oxidase NOX5-S Expression in Human Esophageal Adenocarcinoma Cells.PLoS One. 2016 Feb 22;11(2):e0149735. doi: 10.1371/journal.pone.0149735. eCollection 2016.
86	Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma.Sci Rep. 2019 Mar 26;9(1):5168. doi: 10.1038/s41598-019-41490-w.
87	Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.Surgery. 2005 Nov;138(5):924-31. doi: 10.1016/j.surg.2005.05.007.
88	Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.Genes Chromosomes Cancer. 2012 Apr;51(4):384-93. doi: 10.1002/gcc.21923. Epub 2011 Dec 14.
89	Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus.Tumour Biol. 2017 May;39(5):1010428317708267. doi: 10.1177/1010428317708267.
90	Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.Cancer. 2013 Apr 1;119(7):1321-9. doi: 10.1002/cncr.27910. Epub 2012 Dec 20.
91	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome.BMC Cancer. 2018 Nov 12;18(1):1106. doi: 10.1186/s12885-018-5032-z.
92	Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance.Radiat Res. 2012 Mar;177(3):272-9. doi: 10.1667/rr2776.1. Epub 2012 Jan 3.
93	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.Clin Gastroenterol Hepatol. 2018 Oct;16(10):1598-1606.e4. doi: 10.1016/j.cgh.2018.03.007. Epub 2018 Mar 15.
94	Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma.Clin Cancer Res. 2012 Apr 1;18(7):1936-46. doi: 10.1158/1078-0432.CCR-11-1431. Epub 2012 Feb 10.
95	Aberrant methylation of the Ras-related associated with diabetes gene in human primary esophageal cancer.Anticancer Res. 2013 Nov;33(11):5199-203.
96	Value of histomorphometric tumour thickness and smoothelin for conventional m-classification in early oesophageal adenocarcinoma.World J Gastrointest Oncol. 2017 Nov 15;9(11):444-451. doi: 10.4251/wjgo.v9.i11.444.
97	Authentication and characterisation of a new oesophageal adenocarcinoma cell line: MFD-1.Sci Rep. 2016 Sep 7;6:32417. doi: 10.1038/srep32417.
98	RING finger proteins are involved in the progression of barrett esophagus to esophageal adenocarcinoma: a preliminary study.Gut Liver. 2014 Sep;8(5):487-94. doi: 10.5009/gnl13133. Epub 2014 Feb 24.
99	The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.Genome Biol. 2014 Jul 31;15(7):417. doi: 10.1186/s13059-014-0417-z.
100	Hypermethylation of the GATA gene family in esophageal cancer.Int J Cancer. 2006 Nov 1;119(9):2078-83. doi: 10.1002/ijc.22092.
101	Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia.Am J Pathol. 2001 Jan;158(1):33-40. doi: 10.1016/S0002-9440(10)63941-7.